From the Department of Bizarre Anomalies: Microsoft has suppressed an unexplained anomaly on its network that was routing traffic destined to example.com—a domain reserved for testing purposes—to a ...

Welcome to the STM32 ADC with DMA repository! This project demonstrates how to read multiple sensors using the STM32 microcontroller, specifically the STM32F103C8T6. It leverages the Analog-to-Digital ...

KILLEEN— After more than two decades in uniform, U.S. Army Master Sgt. Fabian Balarezo is living proof that personal growth doesn’t end with rank, and that education can be a bridge between military ...

ADRX-0706, a Nectin-4-targeted antibody-drug conjugate, has earned FDA fast track designation in advanced cervical cancer. The FDA has granted fast track designation to ADRX-0706 for the treatment of ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

NEW YORK--(BUSINESS WIRE)--Flowcode, the enterprise QR code platform delivering unique custom experiences, announced a partnership today with fast growing, emerging snack brand LOVE CORN, marking the ...

For example, Ryder, a national leader in logistics and commercial trucks, has partnered with REIN and Flowcode to utilize QR codes connected to the REIN IX platform in order to embed various financial ...

Flowcode, a marketing technology platform, has partnered with embedded insurance technology company REIN to streamline insurance purchases by making it easier to secure a quote and find coverage ...

Despite some positive trials with new drugs (including immunotherapy) for recurrent cervical cancer, the prognosis for this disease remains poor and additional treatment options are needed. Tisotumab ...

Ahead of the November presidential election, just 19% of Americans say democracy in the United States is a good example for other countries to follow, according to a Pew Research Center survey ...

In the second setback for the HER3 field in days, the FDA has rejected Daiichi Sankyo’s Merck & Co.-partnered antibody-drug conjugate (ADC) patritumab deruxtecan. The drug, also known as HER3-DXd, was ...